Clinical trial
Suppression of Oral HHV8 Shedding With Valganciclovir
NCT00194467 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194467 |
|---|---|
| Title | Suppression of Oral HHV8 Shedding With Valganciclovir |
| Official title | Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir |
| Lead sponsor | University of Washington, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Human Herpesvirus 8 |
| Intervention type | Drug |
| Interventions | valganciclovir, placebo |
| Enrollment | 32 |
| Start date | Dec 1, 2002 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: